Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

AIDS

Volumn 22, Issue 10, 2008, Pages 1224-1226

  Harris, Marianne ^a,c   Larsen, Gerene ^a   Montaner, Julio S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE; 2 PYRROLIDONE DERIVATIVE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MALE; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTIDRUG RESISTANCE;

ADULT; AGED; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 50949112147     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328302f3b5     Document Type: Article

References (7)

1. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:21 75-21 85.
2. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drugresistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
3. Cooper DA, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, et al. 48-week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV-1 [abstract 788]. In: 15th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 3-6, 2008.
4. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loutfy M, et al. 48-week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing antiretroviral therapy with tripleclass resistant HIV-1 [abstract 789]. In: 15th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 3-6, 2008.
5. Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40:413-421.
6. Grinsztejn B, Nguyen B-Y, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 2007; 369:1261-1269.
7. Wenning LA, Hanley W, Stone J, Moreau J, Kost JT, Mangin E, et al. Effect of tipranavir p ritonavir (TPV p RTV) on pharmacokinetics of MK-0518 [abstract A374]. In: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 27-30, 2006.